2009.09.03 – TargeGen Announces Initiation Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myeloproliferative Disease Patients

http://preventclosed.alla.bolognina.biz/2009/09/03/targegen-announces-initiation-of-clinical-trial-of-jak2-inhibitor-tg101348-in-myeloproliferative-disease-patients/

September 3rd, 2009

TargeGen Announces Initiation Of Clinical Trial Of JAK2 Inhibitor TG101348 In Myeloproliferative Disease Patients

TargeGen, Inc. announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.

The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348 was, administered orally, shown to reduce V617F-expressing chamber populations in a dose-dependant manner without adversely impacting normal hematopoeisis. The reduction of V617F-expressing cell populations correlated with improved survival and reduced morbidity. There are no currently approved proper to therapies for PV, ET and PMF. These disorders are estimated to affect around 200,000 patients in the United States and more than twice that unalloyed worldwide.

The current clinical trial is being conducted at multiple centers in the USA. The trial is expected to enroll between 40-80 patients. Matchless goals of this open ID amount escalating protocol include authentication of a maximum tolerated dose (MTD), accumulation of safety figures, measurement of drug to all intents on surrogate markers, biomarkers, and presumptive clinical endpoints.

Near TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen primarily develops small molecule kinase inhibitors that target vascular leakage (edema), vascular proliferation (angiogenesis) and irritation. Edema, angiogenesis and irritation are implicated in the pathology of many major human diseases.

TargeGen initiated operations in 2002 and has raised excellent from top tier venture finances sources. Present-day investors include VantagePoint Gamble Partners, Forward Ventures, Enterprise Partners, Chicago Intumescence Partners, BB BIOTECH VENTURES, Innovis Investments, H&Q Capital Conduct, Pappas Ventures, CTI Spark of life Sciences and other investors.

TargeGen, Inc.
http://www.targegen.com

Bookmark and Share